Hot topics in diabetes
Key takeaways Retatrutide isn't approved yet and isn't expected to launch in the UK until at least mid-2026 In clinical trials, target doses ranged from 0.5mg to 12mg weekly, with the most common being 4mg, 8mg, 9mg and 12mg Different dosing schedules were tested, with most people starting at 2mg and escalating every 4 weeks The 12mg dose produced the most weight loss (up to 28.7% after 68 weeks) Starting at 2mg rather than 4mg helped reduce side effects during escalation First to know Get an email the day retatrutide launches in the UK
If a vendor is marketing GHK-Cu as a weight loss peptide, a muscle-builder, or a guaranteed longevity intervention, that is marketing that exceeds the evidence
And the critical steps you need to take right now to protect your claim, even if you have not decided whether to file
Aalens additive regression model
Vertical integration and capacity expansion-catalyzed by the $16.5B Catalent acquisition-create scale, quality control and distribution reliability that raise the bar for new entrants
:format(webp))
